玻璃体内注射雷珠单抗治疗早产儿视网膜病变

目的　观察玻璃体内注射雷珠单抗治疗早产儿视网膜病变（ｒｅｔｉｎｏｐａｔｈｙｏｆｐｒｅｍａ-ｔｕｒｉｔｙ，ＲＯＰ）的疗效及其安全性。方法　回顾分析了２０１２年１１月至２０１４年５月于北京同仁医院治疗的１７例（３１眼）ＲＯＰ患儿，在４８ｈ内行玻璃体内注射雷珠单抗，对注射后无反应者，重复玻璃体内注射雷珠单抗或联合激光光凝治疗，术后１ｄ、１个月内每周随访观察复诊。结果　所有治疗眼中，单纯行玻璃体内注射雷珠单抗２７眼，玻璃体内注射雷珠单抗联合激光治疗４眼。２８眼进行了一次治疗，３眼经过了二次注射治疗；４眼进行补充视网膜激光治疗。所有的ＲＯＰ治疗均有效，随访期内未见有复发病例。结论　玻璃体内注射雷珠单抗对ＲＯＰ的治疗效果可靠，尤其对于病情严重、全身情况差不能耐受全身麻醉的患儿，其优势明显。

Intravitreal injection of ranibizumab for retinopathy of prematurity

Objective To evaluate the effects and safety of intravitreal injection of ranibizumab for retinopathy of prematurity ( ROP) . Methods A retrospective evaluation was performed of medical records. Data from 17 patients ( 31 eyes) of ROP who had been treated with intravitreal injection of ranibizumab in Beijing Tongren Hospital from November 2012 to May 2014 were analyzed. All patients were treated with intravitreal injection of ranibizumab within 48 hours after diagnose as ROP. If the infants did not respond positively to the treatment , the additional laser treatment was applied. Follow-up examinations were performed after treatment at postoperative I day and I month. Results In the all treatment eyes, only treated with intravitreal injection of ranibizumab were in 27 eyes , and intravitreal injection of ranibizumab combined with laser treatment were in 4 eyes. 28 eyes were treated once ,3 eyes received the second injection ,4 eyes were supplemented by laser treatment. A1l the treatments were effective . and no recurrence was found during the follow-up period. Conclusion The therapeutic effect of intravitreal injection of rarubizumab is reliable, especially for the patients with severe disease , poor general condition not tolerating general anesthesia.